Cheap Ozempic? How millions of Americans with obesity may get access to costly weight-loss drugs
Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 billion proposal from the Biden administration is blessed by President-elect Donald Trump.
Biden proposes Medicare and Medicaid cover costly weight-loss drugs for millions of obese Americans
Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare or Medicaid under a new rule the Biden administration proposed Tuesday morning.
Biden wants Medicare, Medicaid to cover pricey weight loss drugs such as Wegovy
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
Weight-loss drug Zepbound might help manage heart failure
Zepbound, a drug used to help patients lose weight and manage diabetes, may also help those with heart failure, a new trial shows.
Medicare moves to expand coverage for weight-loss drugs Wegovy, Zepbound
The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and Zepbound.
White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs
More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the proposal.
Biden proposes Medicare, Medicaid cover pricey weight-loss drugs for obese Americans
Millions of Americans could soon have access to weight-loss medications that some have called "miracle drugs."
What to Know About Biden’s Plan for Weight-Loss Drugs, Medicaid and Medicare
The Biden administration proposed a rule for Medicare and Medicaid to cover the costs of weight-loss drugs for millions of Americans with obesity.
Biden wants drugs like Wegovy, Ozempic covered by Medicare, Medicaid
Millions of Americans with obesity would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic covered by Medicare and Medicaid under a new rule the Biden administration proposed Tuesday morning.
Biden’s plan for Medicare coverage of weight-loss drugs would drive up costs by billions of dollars
President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Wegovy, Ozempic, Zepbound and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.
Biden Proposes Expanded Medicare, Medicaid Coverage of Obesity Drugs
Current rules for the Medicare and Medicaid government health insurance programs cover the use of drugs such as Mounjaro, Ozempic and Wegovy for certain conditions like diabetes, but not for obesity as a condition on its own.
HealthDay on MSN4h
Zepbound Slashes Diabetes Risk in Obese Users
The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has ...
The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock.
The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly’s ...
Biden wants to cover weight loss meds. RFK Jr. would rather we just eat better.
The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr.
KFDI8h
Biden admin. proposes coverage for weight-loss drugs by Medicare, Medicaid
Share on Facebook Share on Twitter Under a new rule the Biden administration proposed on Tuesday, millions of Americans with ...
Eli Lilly’s Stock Poised for Growth Amid Potential CMS Coverage for Zepbound
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...
BioSpace9h
The Biggest Pharma Share Moves of the Year So Far
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
Investor's Business Daily on MSN1d
Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
BioPharma Dive1d
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is ...